- Home
- RLMD vs CELU Comparison
RLMD vs CELU Comparison
Compare RLMD & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- CELU
- Stock Information
- Founded
- RLMD 2004
- CELU 2016
- Country
- RLMD United States
- CELU United States
- Employees
- RLMD N/A
- CELU N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- CELU Health Care
- Exchange
- RLMD Nasdaq
- CELU Nasdaq
- Market Cap
- RLMD 66.7M
- CELU 64.3M
- IPO Year
- RLMD N/A
- CELU N/A
- Fundamental
- Price
- RLMD $1.99
- CELU $2.05
- Analyst Decision
- RLMD Hold
- CELU Strong Buy
- Analyst Count
- RLMD 2
- CELU 1
- Target Price
- RLMD $1.00
- CELU $6.00
- AVG Volume (30 Days)
- RLMD 517.7K
- CELU 165.3K
- Earning Date
- RLMD 11-06-2025
- CELU 08-29-2025
- Dividend Yield
- RLMD N/A
- CELU N/A
- EPS Growth
- RLMD N/A
- CELU N/A
- EPS
- RLMD N/A
- CELU N/A
- Revenue
- RLMD N/A
- CELU $44,590,000.00
- Revenue This Year
- RLMD N/A
- CELU N/A
- Revenue Next Year
- RLMD N/A
- CELU $76.00
- P/E Ratio
- RLMD N/A
- CELU N/A
- Revenue Growth
- RLMD N/A
- CELU 4.45
- 52 Week Low
- RLMD $0.24
- CELU $1.00
- 52 Week High
- RLMD $3.98
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- RLMD 59.73
- CELU 38.22
- Support Level
- RLMD $1.89
- CELU $2.00
- Resistance Level
- RLMD $2.84
- CELU $2.20
- Average True Range (ATR)
- RLMD 0.28
- CELU 0.17
- MACD
- RLMD 0.01
- CELU 0.03
- Stochastic Oscillator
- RLMD 37.96
- CELU 15.33
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.